It is concluded that the prognosis of older adults with AML undergoing intensive chemotherapy remained poor and those carrying adverse prognostic features should avoid this approach. The new alternative therapies,...
To investigate the cumulative incidence of second malignancy and the competing risk of death due to any other cause in patients who were treated for childhood acute myeloid leukemia (AML), we analyzed the outcomes in a cohort of 501 patients who were tre
NUP98-NSD1 stands as an independent prognostic factor for adverse outcomes. For both pediatric and adult AML patients positive for NUP98-NSD1, the 4-year event-free survival(EFS) rate is markedly low. Initial responses to conventional chemotherapy are suboptimal in patients positive for NUP98-NSD...
FLAG (fludarabine plus high dose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of poor risk myeloid leukaemias.Leukemia. 1994;8:1842–1846. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with AML.N Engl J Med. 1994;331:...
Despite major recent advances in the understanding of the molecular biology of the disease, the treatment of acute myeloid leukemia (AML) in adults remains challenging. For the 75% of AML patients older than 60 years, currently available treatments produce significant toxicity with poor overall respo...
In Nplate®(romiplostim) clinical trials of patients with myelodysplastic syndromes (MDS) and severe thrombocytopenia, progression from MDS to acute myelogenous leukemia (AML) has been observed. Nplate®is not indicated for the treatment of thrombocytopenia due to MDS or any cause of thrombocytopenia...
Acute myeloid leukemia (AML) is the most aggressive and prevalent form of leukemia in adults. The gold-standard intervention revolves around the use of chemotherapy, and in some cases hematopoietic stem cell transplantation. Drug resistance is a frequent complication resulting from treatment, as it ...
Another oral HMA agent that has been approved in the USA, but not for management of MDS, is the oral formulation of AZA CC-486, which is currently approved as a maintenance therapy for AML patients who have not been able to complete curative intent therapy after induction chemotherapy. In ...
combination of the best of the four induction regimens (7 and 3 infusion) and the better of the two maintenance schedules (s.c. ara-C) had a median remission duration of 22 mo and a median survival of 35 mo (the longest reported in a prospective randomized trial of therapy for AML)....
Current status of reduced intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia Allogeneic stem cell transplantation (allo-SCT) is the most efficient antileukemic treatment for acute myeloblastic leukemia (AML). However, elderly patien... D Blaise,N Vey,C Faucher,......